Novan Therapeutics Company Profile

20:35 EST 18th December 2018 | BioPortfolio

News Articles [700 Associated News Articles listed on BioPortfolio]

Novan Releases Clinical Results for Skin Disease Treatment

Following positive clinical trial results in the Phase 1b trial of SB414, Novan Therapeutics announced on Monday (August 20) it will move forward with its testing indications. The post Novan Releases ...

Novan reports positive data from two Phase lb trials of SB414

Novan has reported positive results from two complementary Phase lb trials to investigate the safety, tolerability and initial efficacy of...Read More... The post Novan reports positive data from two ...

Novan to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., June 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that members of management are scheduled to attend the 2018 Cantor Dermatol...

Novan Announces Promising Clinical Results with SB414

In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxid...

Novan Receives FDA Guidance for SB204 and Acne Indication

Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24, 2...

Novan Creates Dedicated Women’s Health Business Unit

Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical ca...

Novan Announces Corporate Update Conference Call and Webcast

MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November...

Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract

Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filingNew incentive plan is aligned with the achievement of two specific stockholder value targets and is intend...

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1288 Associated Companies listed on BioPortfolio]

Novan Therapeutics

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Novan Therapeutics" on BioPortfolio

We have published hundreds of Novan Therapeutics news stories on BioPortfolio along with dozens of Novan Therapeutics Clinical Trials and PubMed Articles about Novan Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novan Therapeutics Companies in our database. You can also find out about relevant Novan Therapeutics Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record